A Study to Evaluate the Efficacy and Safety of AD-209

Hypertension, Essential Clinical Trial

Official title:
A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of AD-209

Clinical Trial Description

Condition or disease : hypertension Intervention/treatment Drug : AD-209 Drug : AD-209-1A Drug : AD-209-1B Drug : AD-209-1C Drug : AD-209 Placebo Drug : AD-209-1 Placebo Phase : Phase 2 ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05631990
Study type	Interventional
Source	Addpharma Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	April 5, 2023
Completion date	November 27, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01227603` - Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions	Phase 1
Completed	`NCT03258489` - Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients	N/A
Terminated	`NCT02245230` - Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension	Phase 1
Completed	`NCT02466490` - Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension	Phase 3
Completed	`NCT01350609` - Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed	Phase 1
Completed	`NCT01303783` - Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension	Phase 2
Not yet recruiting	`NCT04332562` - The Association Between Serum β-hydroxybutyrate and Levels of Systemic Hypertension	N/A